ORAMED PHARMACEUTICALS INC (ORMP) Fundamental Analysis & Valuation

NASDAQ:ORMP • US68403P2039

Current stock price

3.44 USD
+0.02 (+0.58%)
At close:
3.5 USD
+0.06 (+1.74%)
After Hours:

This ORMP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. ORMP Profitability Analysis

1.1 Basic Checks

  • ORMP had positive earnings in the past year.
  • In the past year ORMP has reported a negative cash flow from operations.
  • In the past 5 years ORMP reported 4 times negative net income.
  • In the past 5 years ORMP always reported negative operating cash flow.
ORMP Yearly Net Income VS EBIT VS OCF VS FCFORMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

  • ORMP has a better Return On Assets (19.89%) than 97.92% of its industry peers.
  • ORMP's Return On Equity of 21.57% is amongst the best of the industry. ORMP outperforms 92.19% of its industry peers.
Industry RankSector Rank
ROA 19.89%
ROE 21.57%
ROIC N/A
ROA(3y)-10.8%
ROA(5y)-15.12%
ROE(3y)-11.25%
ROE(5y)-17.59%
ROIC(3y)N/A
ROIC(5y)N/A
ORMP Yearly ROA, ROE, ROICORMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

  • ORMP has a Profit Margin of 2192.60%. This is amongst the best in the industry. ORMP outperforms 99.48% of its industry peers.
  • ORMP does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 2192.6%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORMP Yearly Profit, Operating, Gross MarginsORMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ORMP Health Analysis

2.1 Basic Checks

  • ORMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for ORMP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ORMP Yearly Shares OutstandingORMP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ORMP Yearly Total Debt VS Total AssetsORMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • ORMP has an Altman-Z score of 4.49. This indicates that ORMP is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of ORMP (4.49) is better than 74.48% of its industry peers.
  • ORMP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.49
ROIC/WACCN/A
WACC8.7%
ORMP Yearly LT Debt VS Equity VS FCFORMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 22.24 indicates that ORMP has no problem at all paying its short term obligations.
  • ORMP's Current ratio of 22.24 is amongst the best of the industry. ORMP outperforms 93.23% of its industry peers.
  • A Quick Ratio of 22.24 indicates that ORMP has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 22.24, ORMP belongs to the top of the industry, outperforming 93.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 22.24
Quick Ratio 22.24
ORMP Yearly Current Assets VS Current LiabilitesORMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ORMP Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 924.83% over the past year.
EPS 1Y (TTM)924.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -19.32% on average over the next years. This is quite bad
  • ORMP is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y-186.56%
EPS Next 2Y-60.1%
EPS Next 3Y-35.75%
EPS Next 5Y-19.32%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

ORMP Yearly Revenue VS EstimatesORMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2025 500K 1M 1.5M 2M 2.5M
ORMP Yearly EPS VS EstimatesORMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

2

4. ORMP Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 2.32 indicates a rather cheap valuation of ORMP.
  • Based on the Price/Earnings ratio, ORMP is valued cheaply inside the industry as 97.92% of the companies are valued more expensively.
  • ORMP's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.21.
  • The Forward Price/Earnings Ratio is negative for ORMP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 2.32
Fwd PE N/A
ORMP Price Earnings VS Forward Price EarningsORMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORMP Per share dataORMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • A cheap valuation may be justified as ORMP's earnings are expected to decrease with -35.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-60.1%
EPS Next 3Y-35.75%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. ORMP Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 7.31%, ORMP is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.64, ORMP pays a better dividend. On top of this ORMP pays more dividend than 98.44% of the companies listed in the same industry.
  • ORMP's Dividend Yield is rather good when compared to the S&P500 average which is at 1.89.
Industry RankSector Rank
Dividend Yield 7.31%

5.2 History

  • ORMP does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
ORMP Yearly Dividends per shareORMP Yearly Dividends per shareYearly Dividends per share 2026 0.05 0.1 0.15 0.2

5.3 Sustainability

DPN/A
EPS Next 2Y-60.1%
EPS Next 3Y-35.75%
ORMP Yearly Income VS Free CF VS DividendORMP Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

More info and screens

Find the best dividend stocksShow peers with best dividend

ORMP Fundamentals: All Metrics, Ratios and Statistics

ORAMED PHARMACEUTICALS INC

NASDAQ:ORMP (4/6/2026, 8:01:34 PM)

After market: 3.5 +0.06 (+1.74%)

3.44

+0.02 (+0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-26
Earnings (Next)08-12
Inst Owners27.78%
Inst Owner Change0%
Ins Owners15.95%
Ins Owner Change14.85%
Market Cap136.91M
Revenue(TTM)N/A
Net Income(TTM)43.85M
Analysts43.33
Price Target6.38 (85.47%)
Short Float %1.68%
Short Ratio3.19
Dividend
Industry RankSector Rank
Dividend Yield 7.31%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date01-16
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1852.45%
Min EPS beat(2)859.8%
Max EPS beat(2)2845.1%
EPS beat(4)3
Avg EPS beat(4)510.54%
Min EPS beat(4)-1762.75%
Max EPS beat(4)2845.1%
EPS beat(8)6
Avg EPS beat(8)-569.36%
EPS beat(12)10
Avg EPS beat(12)-366.78%
EPS beat(16)11
Avg EPS beat(16)-276.91%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)92.31%
PT rev (3m)92.31%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 2.32
Fwd PE N/A
P/S 68.46
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB 0.67
EV/EBITDA N/A
EPS(TTM)1.48
EY43.02%
EPS(NY)-1.29
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0.05
BVpS5.11
TBVpS5.11
PEG (NY)N/A
PEG (5Y)N/A
Graham Number13.04
Profitability
Industry RankSector Rank
ROA 19.89%
ROE 21.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 2192.6%
GM N/A
FCFM N/A
ROA(3y)-10.8%
ROA(5y)-15.12%
ROE(3y)-11.25%
ROE(5y)-17.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.75%
Cap/Sales 0.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.24
Quick Ratio 22.24
Altman-Z 4.49
F-Score5
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)324.08%
Cap/Depr(5y)449.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)924.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-186.56%
EPS Next 2Y-60.1%
EPS Next 3Y-35.75%
EPS Next 5Y-19.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y0.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.49%
OCF growth 3YN/A
OCF growth 5YN/A

ORAMED PHARMACEUTICALS INC / ORMP Fundamental Analysis FAQ

What is the fundamental rating for ORMP stock?

ChartMill assigns a fundamental rating of 4 / 10 to ORMP.


What is the valuation status for ORMP stock?

ChartMill assigns a valuation rating of 2 / 10 to ORAMED PHARMACEUTICALS INC (ORMP). This can be considered as Overvalued.


Can you provide the profitability details for ORAMED PHARMACEUTICALS INC?

ORAMED PHARMACEUTICALS INC (ORMP) has a profitability rating of 3 / 10.


What is the valuation of ORAMED PHARMACEUTICALS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ORAMED PHARMACEUTICALS INC (ORMP) is 2.32 and the Price/Book (PB) ratio is 0.67.